



Published in final edited form as:

Mult Scler. ; : 1352458518771873. doi:10.1177/1352458518771873.

Leptomeningeal enhancement of the spinal cord in sarcoidosis

Martina Absinta, MD, PhD

Translational Neuroradiology Section, Division of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA

Keywords

Neurosarcoidosis; Differential Diagnosis; Magnetic Resonance Imaging (MRI)

Spinal cord involvement is a rare complication of sarcoidosis (<1% cases; mean age ~40-45 years old, slight male prevalence). The diagnosis is especially difficult when spinal cord involvement is the initial presenting symptom or when no other symptoms of sarcoidosis are evident.¹ Given the wide spectrum of clinical presentation and disease course of spinal sarcoidosis (monophasic, relapsing, subacute, worsening over time), initial differential diagnosis can span from inflammatory myelitis [multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMO), acute transverse myelitis], infectious diseases and neoplasms.¹ On postcontrast T1-weighted MR images, intramedullary enhancement with cord swelling can affect the cervical and/or thoracic cord and can vary in extent [small nodular or longitudinally extensive (> 3 cord segments)] and location [central, dorsal or in combination (trident sign) on axial images].²⁻⁷ Cord atrophy might result after the resolution of the inflammatory process. Confirmation of spinal sarcoidosis often requires biopsy of mediastinal lymph nodes or, as in some of the reported cases,³⁻⁵ of the spinal cord itself. The availability of immunosuppressive treatments¹ prompts for a timely diagnosis and appropriate intervention to avoid neurological sequelae.

In “Concurrent LETM and nerve root enhancement in Spinal Neurosarcoid: a case series”, Peng and colleagues report 3 cases of longitudinally-extensive spinal cord involvement as presenting event of biopsy-proven sarcoidosis. In line with previous reports,²⁻⁷ intramedullary enhancing cord lesions with concomitant leptomeningeal and nerve root (including cauda equina) enhancement can help in the differential diagnosis, as these findings are not typical of inflammatory myelitis in MS and NMO.^{7, 8} Differently from cord leptomeningeal enhancement, focal enhancement of the leptomeninges covering the brain (seen on delayed postcontrast 3D T2-FLAIR) should not be considered a major diagnostic red flag, since has been shown to occur frequently in MS and other neuroinflammatory conditions (including neurosarcoidosis) as well as neurotropic viral infections (HIV and HTLV).^{9, 10}

Acknowledgments

The author is supported by the Intramural Research Program of NINDS, by a Marilyn Hilton Award for Innovation in MS research from the Conrad N. Hilton Foundation (grant #EIN 15-20858115) and by a National Multiple Sclerosis Society (NMSS) fellowship award (grant #FG 2093-A-1).

References

1. Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. *J Neurol*. 2015; 262:258–267. [PubMed: 25194844]
2. Junger SS, Stern BJ, Levine SR, Sipos E, Marti-Masso JF. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. *Neurology*. 1993; 43:333–337. [PubMed: 8437698]
3. Kumar N, Frohman EM. Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. *Arch Neurol*. 2004; 61:586–589. [PubMed: 15096410]
4. Saleh S, Saw C, Marzouk K, Sharma O. Sarcoidosis of the spinal cord: literature review and report of eight cases. *J Natl Med Assoc*. 2006; 98:965–976. [PubMed: 16775923]
5. Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. *Am J Med Sci*. 2014; 347:195–198. [PubMed: 23364469]
6. Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. *Neurology*. 2016; 87:743–744. [PubMed: 27527540]
7. Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. *Ann Neurol*. 2016; 79:437–447. [PubMed: 26677112]
8. Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Nat Rev Neurol*. 2018
9. Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. *Neurology*. 2015; 85:18–28. [PubMed: 25888557]
10. Absinta M, Cortese IC, Vuolo L, et al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. *Neurology*. 2017; 88:1439–1444. [PubMed: 28283598]